Skip to content

All Lessons

Overview of FDA’s Engagement in Trade Policy

Overview of ICH M13 Guideline Series

Patient Engagement (REdI 2024 – Biologics Track)

Pharmacology & Toxicology in the Investigator’s Brochure

Plenary (REdI 2024 Conference)

Postmarketing Surveillance for Product Safety in Pregnancy (REdI 2024 – Biologics Track)

Pre-Abbreviated New Drug Application (ANDA) Meetings: Process and Best Practices

Presentations: CFSAN Updated “Healthy” Nutrient Content Claim: Final Rule

Product Specific Guidance (PSG) Program Overview

Programs Next Steps & Poll Questions (BsUFA III Science Pilot Program: Progress Update)

Project Managing Drug Assessors Under GDUFA III Regulations

Q&A Session 1-1 (FDA Compounding Conference 2025)

Q&A Session 1-2 (FDA Compounding Conference 2025)

Q&A with Session Five Speakers (REdI 2024 – Biologics Track)

Q&A with Session Four Speakers (REdI 2024 – Biologics Track)

Q&A with Session One Speakers (REdI 2024 – Biologics Track)

Q&A with Session Seven Speakers (REdI 2024 – Biologics Track)

Q&A with Session Six Speakers (REdI 2024 – Biologics Track)

Q&A with Session Three Speakers (REdI 2024 – Biologics Track)

Q&A with Session Two Speakers (REdI 2024 – Biologics Track)

Question & Answer Panel One (Electronic Drug Registration and Listing 2024)

Question & Answer Panel Two (Electronic Drug Registration and Listing 2024)

Question & Answer Session (IDMP)

Question & Answer Session (M13A: Bioequivalence)

Question & Answer Session (Navigating Controlled Correspondences)

1 … 7 8 9 10 11 … 13
Share: